Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Coya Therapeutics, Inc. - Common Stock
(NQ:
COYA
)
5.120
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Coya Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results
August 12, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer’s Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid
August 02, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
July 31, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic
June 20, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology
June 11, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology
June 03, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index
May 28, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease
May 22, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)
May 20, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results
May 09, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
April 26, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics to Participate in the Mizuho Neuroscience Summit
April 22, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
April 18, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
April 08, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
March 19, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics to Participate in BTIG Fireside Discussion
March 12, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference
March 12, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference
March 06, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference
February 29, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology Conference
February 22, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a “Pipeline in a Product”
February 21, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases
February 13, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology Conference
January 29, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call Series
January 18, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral Sclerosis
January 16, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of COYA 302 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
January 05, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Mr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc.
December 20, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics’ CEO Dr. Howard Berman’s Letter to Stockholders
December 13, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announces Closing of $26.5 Million Private Placement
December 12, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announces $26.5 Million Private Placement
December 06, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.